Aug 25, 2026 07:05AM
Aug 25, 2026 07:00AM
Aug 25, 2026 07:00AM
Jul 13, 2026 02:01AM
Jul 13, 2026 02:00AM
Jul 13, 2026 02:00AM
Jul 13, 2026 02:00AM PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Jul 2, 2026 02:01AM
Jul 2, 2026 02:01AM
Jun 10, 2026 01:14PM
Jun 9, 2026 02:00AM
Jun 9, 2026 02:00AM
May 13, 2026 07:00AM
Apr 29, 2026 05:53AM PureTech plans to delist from NASDAQ, focus trading on London exchange
Apr 29, 2026 02:01AM
Apr 29, 2026 02:00AM
Apr 27, 2026 07:05AM
Apr 27, 2026 07:05AM
Apr 22, 2026 07:00AM
Apr 22, 2026 07:00AM
Apr 13, 2026 02:05AM PureTech Health: Notice of Results
Apr 2, 2026 08:19AM
Apr 2, 2026 08:19AM
Apr 2, 2026 07:08AM
Apr 2, 2026 07:08AM
Mar 25, 2026 02:05PM
Mar 25, 2026 02:04PM
Feb 25, 2026 02:00AM PureTech to Present at the Leerink Partners Global Healthcare Conference
Feb 19, 2026 12:37PM
Feb 19, 2026 12:36PM
Jan 6, 2026 07:00AM
Dec 18, 2025 02:00AM
Dec 18, 2025 02:00AM
Dec 8, 2025 02:00AM
Dec 8, 2025 02:00AM PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
Dec 5, 2025 01:00PM
Dec 5, 2025 01:00PM
Nov 3, 2025 11:37AM
Nov 3, 2025 09:00AM
Oct 22, 2025 04:44AM
Oct 22, 2025 02:00AM
Sep 29, 2025 02:00AM PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
Sep 11, 2025 07:05AM
Sep 11, 2025 07:05AM
Aug 28, 2025 02:00AM
Aug 21, 2025 07:01AM
Aug 21, 2025 07:00AM
Aug 18, 2025 02:00AM
Aug 13, 2025 12:16PM Vedanta Biosciences' ulcerative colitis drug fails phase 2 trial
Aug 13, 2025 12:16PM

329,877 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All